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Abstract
Background: High doses of pooled polyclonal IgG are commonly used to treat numerous autoimmune diseases. Their mode
of action nevertheless remains only partially explained. At the same time, until now, no early biological marker has been
able to predict their efficacy.
Methodology/Principal Findings: In a first pilot retrospective analysis, we reviewed white blood cell counts and blood
smears in consecutive patients with autoimmune disease (n=202) and non-autoimmune disease (n=104). Autoimmune
patients received either intravenous immunoglobulin (IVIg, n=103), plasma exchange (n=78) or no specific treatment
(n=21). We then prospectively monitored consecutive autoimmune patients with IVIg injection (n=67), or without any
specific treatment (n=10) using the same routine laboratory tests, as well as flow cytometry. Both retrospective and
prospective analyses identified large plasma-cell mobilization exclusively in IVIg-treated autoimmune patients 7 days after
initiation of treatment. The majority of IVIg-mobilized plasma cells were immature HLA-DR
high/CD138
low/CXCR4
low plasma
cells expressing intracellular immunoglobulin G which were neither IVIg- nor human IgG-specific. Importantly, we found a
strong negative correlation between the absolute number of IVIg-mobilized plasma cells and time to improve neurological
function in both retrospective and prospective studies of Guillain-Barre ´ syndrome (GBS), (r=20.52, p=0.0031, n=30,
r=20.47, p=0.0028, n=40, respectively).
Conclusions/Significance: IVIg promotes immature plasma-cell mobilization in patients with GBS, chronic inflammatory
demyelinating polyneuropathy, myasthenia gravis and inflammatory myopathy. Prominent day 7 plasma-cell mobilization is
a favourable prognostic marker in patients with GBS receiving IVIg treatment.
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Introduction
Polyclonal IgG pooled from the serum of thousands of donors is
widely used not only to confer passive protection to immune
deficient patients but also as an anti-inflammatory agent [1].
Intravenous immunoglobulin (IVIg) therapy is approved by Food
and Drug Administration for the treatment of immune thrombo-
cytopenic purpura, Kawasaki disease, primary immunodeficiency,
bone marrow transplantation, chronic B-cell lymphocytic leuke-
mia, and pediatric HIV infection [2]. Off label use is common in
several autoimmune conditions such as Guillain-Barre ´ syndrome
(GBS), chronic inflammatory demyelinating polyneuropathy
(CIDP), myasthenia gravis (MG), inflammatory myopathy (IM),
and multiple sclerosis, making it a major drug expenditure item
[2]. Until now, there has existed no biological marker which may
be used to evaluate the efficacy of this treatment. The lack of a
biological marker is particularly troublesome when trying to
evaluate the efficacy of IVIg during the course of chronic
autoimmune diseases such as CIDP, MG and IM.
GBS is an autoimmune polyneuropathy, characterized by
precedent infection and acutely progressive motor weakness. GBS
affects 0.4–4.0 cases per 100,000 per year, and represents the most
common cause of acute neuromuscular paralysis [3]. Older age,
preceding gastro-intestinal infection, and rapid onset of severe motor
weakness have been demonstrated to be adverse prognostic factors
[4,5]. Although IVIg has been shown to hasten the recovery of
neurological function as efficiently as plasma exchange (PE), the
mortality remains 5–10% in GBS [6,7]. Until now, it has been
impossible to predict which patient will benefit from a single course
of IVIg, and which will need a more individualized treatment.
PLoS ONE | www.plosone.org 1 May 2008 | Volume 3 | Issue 5 | e2109We report here that IVIg induces a peripheral mobilization of
plasma cells in GBS, CIDP, MG and IM patients 7 days after
initiation of treatment. Our most remarkable finding is that
prominent IVIg-mobilized plasmacytosis correlates with faster
recovery of neurological function in patients with GBS.
Materials and Methods
Objectives
The mode of action of IVIg remains only partially explained.
We aimed to identify a biological marker to predict IVIg efficacy
in autoimmune diseases.
Participants
Fifty consecutive patients with GBS (M/F 31/19, median age 57,
range 15–84), hospitalized in our institution between June 2004 and
June 2007, were prospectively recruited. Three control autoimmune
disease groups consisted of consecutive patients with CIDP (12/2,
52, 30–73), MG (4/3, 70, 19–94), and IM (2/4, 30, 23–57). Only
GBS, CIDP, and MG patients were naı ¨ve of any previous
immunomodulation therapy. Healthy bone marrow donors (2
men, 26, 32 years) and healthy controls (10/12, 39, 22–62) were
enrolled in order to study medullary or circulating plasma cells.
Medical records of 157 GBS patients (91/66, 47, 15–83),
referred to our institution between April 1990 and May 2004,
were reviewed. We also analyzed medical records of consecutive
autoimmune patients treated with IVIg (myasthenic respiratory
crisis, 16/22, 58, 18–94, CIDP, 3/4, 55, 30–81) and consecutive
non-autoimmune patients without immunomodulatory treatments
(61/43, 53, 19–92, encephalitis n=30, cerebral abscess n=2,
Lyme disease n=1, botulism n=1, status epilepticus n=35,
cerebral vascular disease n=25, brain contusion n=2, amyotro-
phic lateral sclerosis n=8), admitted at our institution’s neurolog-
ical intensive care unit (ICU) for more than 14 days between April
1997 and May 2004.
All patients satisfied clinical diagnostic criteria of GBS [8],
CIDP [9], MG [10] and IM [11]. We excluded GBS patients with
serious pre-existing disease (lymphoma n=1, colon cancer n=2,
cholangiocarcinome n=1, hepatic abscess n=1, toxoplasmosis
n=1).
Ethics
The study was performed according to the Helsinki declaration.
The ethics committee of Pitie ´-Salpe ˆtrie `re Hospital approved the
study, and signed informed consent was obtained from all patients
participating in the prospective study.
Assessments
The same senior neurologist (F.B.) examined all GBS patients
and assessed GBS disability-grade [12]. GBS disability-grades
were: 0=healthy, 1=minor symptoms and capable of running;
2=able to walk 5 m or more without assistance but unable to run;
3=able to walk 5 m across an open space with help; 4=chair-
bound/bedbound: unable to walk as in 3; 5=requiring assisted
ventilation for at least part of the day; 6=dead. We evaluated
treatment efficacy by time to one GBS disability-grade improve-
ment, capacity to walk independently at 2 months, and the need
for and duration of artificial ventilation time.
Treatments
All non-ambulant GBS patients were treated on day of
admission (day 0). PE was the first line treatment between April
1990 and April 1997, and IVIg (0.4 g/kg/day, Tegeline, LFB
laboratories, Les Ulis, France) has been the preferred treatment
since then. PE-treated GBS patients with more than 4 disability-
grade received six 50 mL/kg PE (n=61), while patients with 3
disability-grade received only three PE courses (n=17). GBS
patients received IVIg for 5 days if their disability-grade was at
least 4 (n=81), or 3 days for grade 3 (n=17). All CIDP patients in
the retrospective study showed respiratory failure (n=7), and
therefore received IVIg for 4 days and oral prednisolone (1 mg/
kg/day), while CIDP patients in the prospective study received
IVIg only (n=14). All MG patients (n=45) received IVIg for 4
days and oral prednisolone (1 mg/kg/day). All IM patients (n=6)
received IVIg for 4 days after receiving intravenous pulse
methylprednisolone (1 g/day) for 3 days.
Routine enumeration of plasma cells
White blood cell count with 5 differentials was carried out on a
XE2100 (SYXMEX) hematology analyzer, and plasma cell count
was confirmed by blood smear exam after May Grunwald Giemsa
staining.
Cytometric analysis
Whole blood was collected at admission, and every 7 days
during 28 days in the prospective population. Briefly, 200 mlo f
heparinized whole blood was incubated for 20 minutes at room
temperature with various combinations of monoclonal antibodies.
The following antibodies were used: with anti-CD19 allophyco-
cyanin mAb (clone HIB19), anti-CD27 phycoerythrin mAb (clone
M-T271), anti-CD27 fluorescein isothiocyanate (FITC) mAb
(clone M-T271), anti-CD45 FITC (clone 2D1), anti-CD138
peridinin chlorophyll protein-cyanin 5.5 mAb (clone MI15), anti-
CXCR4 phycoerythrin mAb (clone 12G5), anti-HLA-DR phyco-
erythrin-cyanin 7 mAb (clone L243), anti-CD38 FITC mAb (clone
HIT2), anti-IgG FITC mAb (clone G18-145), anti-IgM FITC
mAb (clone G20-127) (all from Becton Dickson; San Diego; CA)
and human IgG FITC (Sigma; St. Louis; USA). IVIg FITC was
prepared by incubation of 20 ml of 5 mg/ml FITC (Sigma) and
500 ml of 2 mg/ml IVIg (LFB) solutions for 2 hours. Unbound
FITC was removed by dialysis against 0.1 M Tris-Cl, 0.2 M NaCl
(Sigma) pH 7.4 over 2 days. For intracellular staining, cells were
fixed with 1% paraformaldehyde (Sigma) for 20 minutes at room
temperature after surface staining, and then permeabilized with
0.1% saponin (Sigma) before intracellular staining. Analyses were
performed using a FACS Calibur and CellQuest Pro software
(Becton Dickson). Absolute numbers of various CD19
+CD27
high
cell subsets were calculated per ml of blood, based on the
frequencies of CD45
+CD19
+CD27
high cells among total CD45
+
peripheral blood mononuclear cells (PBMCs).
Statistical analysis
Proportions of patients between groups were compared using
Fisher exact test. Mean values between two groups were compared
by use of Mann-Whitney U test. Correlation was analyzed using
Spearman test. Time to one disability-grade improvement
comparison between two groups was performed using the log-
rank test. In all statistical analysis, p values ,0.05 were considered
as statistically significant. Data were analyzed using StatView
H
(SAS Institute, Cary, NC, USA).
Results
Demonstration of IVIg-induced plasmacytosis through
retrospective analysis of autoimmune patients.
GBS represents a particularly attractive study model of
autoimmunity insofar as it represents an acutely progressive
polyneuropathy. A precipitating infection is frequently suspected,
IVIg-Related Plasmacytosis
PLoS ONE | www.plosone.org 2 May 2008 | Volume 3 | Issue 5 | e2109and the date of onset of neurological symptom is known. It
therefore seemed to us particularly interesting to study in those
patients the variations of the different leukocyte subpopulations.
We detected a very large population of circulating plasma cells in
numerous GBS afflicted patients treated with IVIg. A retrospective
analysis allowed us to determine that this plasmacytosis was
maximal on the 7
th day after initiating treatment (283 6 343 cells/
ml, n=30, mean 6 SD; Figure 1A upper panel). This effect is
likewise found in patients treated for CIDP or for MG (107 6 31
cells/ml, n=6, 223 6 272 cells/ml, n=21, respectively; Figure 1A
middle and lower panels). Therefore, this anomaly does not seem
linked to a particular pathologic condition, but rather to IVIg
treatment.
In order to confirm an association between IVIg and the
observed plasmacytosis, we analyzed GBS patients having received
PE only. We ensured that treatments with PE (n=78) or IVIg
(n=58) were administered in isolation of other therapies, notably
the absence of associated steroids. Furthermore, the two groups
were homogeneous in terms of prognostic factors, including age
(p=0.98), previous diarrhoea (p=0.50) and intervals from disease
onset to treatment initiation (p=0.09). We also included a third
group of GBS patients (n=21) that received no specific treatment
whatsoever over the course of their hospitalization, however this
group would obviously represent patients who were less severely
afflicted, compared with IVIg-treated patients (p=0.0008). In all
these groups, we examined plasma-cell levels during a 14-day
period following hospitalization. Peripheral blood plasmacytosis
was not detected in patients treated with PE or in those without
specific treatment (Figure 1B upper and middle panels). Impor-
tantly, the IVIg- and PE-treatment groups were homogeneous in
terms of disability-grade at disease nadir (p=0.29) and rate of
improvement of neurological function (p=0.84).
Although peripheral blood plasmacytosis was not detected in
patients treated with PE, we were still concerned with the fact that
this anomaly could simply reflect common infectious complica-
tions, and addressed this issue in two ways. Firstly, we verified that
mean maximal plasma cell counts were not more elevated in IVIg-
treated GBS patients with recorded infectious complications
(pneumonia n=24, septicaemia n=1) than in the others during a
60-day period following hospitalization (278 6 382 cells/ml, n=25
vs 307 6 410 cells/ml, n=33, p=0.33, data not shown). Secondly,
we reviewed medical records of consecutive non-autoimmune ICU-
hospitalized patients who never received immunomodulation
therapy but who were exposed to the same infectious hazards. In
this non-autoimmune group, plasmacytosis was rarely detected
(Figure 1B, lower panel), and mean plasma cell counts 7 days after
admission (1.8 6 17 cells/ml, n=96) were significantly less elevated
than in IVIg-treated patients (GBS: 283 6 343 cells/ml, n=30,
p,0.0001, CIDP: 107 6 31 cells/ml, n=6, p,0.0001, MG: 223 6
272 cells/ml, n=21, p,0.0001, data not shown). Importantly, the
presence of plasmacytosis in non-autoimmune patients was always
associated with sepsis, and sepsis-related plasmacytosis never
exceeded 200 cells/ml during the 14-day hospitalization (54–187
cells/ml, n=9). Altogether, ittherefore seems reasonable to conclude
that a prominent plasmacytosis exceeding 200 cells/ml 7 days after
treatment was IVIg-induced.
Confirmation of IVIg-induced plasmacytosis through
prospective analysis of autoimmune patients.
We next examined if the data gathered during our retrospective
analysis could be confirmed in a consecutive population of GBS,
CIDP, MG and IM patients. Non-ambulant GBS patients and
CIDP patients were treated with IVIg, whereas MG and IM
patients received IVIg and steroids. Using flow cytometry, high
CD27 expression on CD19
+ B cells allows us to distinguish plasma
cells from other CD19
+ B cells (Figure 2A) [13,14]. A longitudinal
analysis of these subpopulations was performed just prior to the
start of treatment with IVIg and every 7 days during 1 month
(Figure 2B). Compared to baseline values (day 0), one finds on the
7
th day a very significant mobilization of circulating
CD19
+CD27
high plasma cells in IVIg-treated patients (Figure 2).
Importantly, IVIg-mobilized CD19
+CD27
high cell counts strongly
correlated with plasma cell counts measured by blood smears
(r=0.94, p,0.0001, n=67, data not shown), indicating that the
same type of plasma cell was indeed monitored at day 7 of IVIg in
both retrospective and prospective studies.
In comparison, levels of absolute CD19
+CD27
high plasma cell
counts remained unchanged during the first week following
admission in ambulant GBS patients without any specific
treatment (5.9 6 2.4 cells/ml vs 6.1 6 4.2 cells/ml, n=10,
p=0.53, data not shown).
Mobilization of immature antibody secreting cells 7 days
post-IVIg.
The circulating plasma cells we observed could correspond to
recently generated and/or highly differentiated plasma cells.
Recently, downregulation of HLA-DR [15], and upregulation of
CD138 [16] and CXCR4 [17,18] have been shown to be
characteristic features of mature plasma cells exiting from the bone
marrow. We first verified that the IVIg-mobilized CD19
+CD27
high
cells contained IgG, and co-expressed CD38 and CD138 (Figure
S1A). In addition, their numbers were clearly proportional to the
number of cells capable of secreting IgG antibodies in vitro in
response to a non-specific stimulus (r=0.99, p=0.0028, n=6;
Figure S1B and Methods S1).
We next revealed that the majority of IVIg-mobilized plasma
cells were CXCR4
low, CD138
low, and HLA-DR
high, and as such,
relatively immature (Figure 3A left panel, B-C). Here, medullary
cells from a healthy control were taken as reference in order to
present CXCR4, CD138, and HLA-DR levels, typically associated
with terminal differentiation into mature plasma cells in the bone
marrow (Figure 3A, right panel).
We further clarified that plasma-cell mobilization was not the
mere consequence of an immunization against IVIg. PBMCs were
stained in vitro with fluorescently labeled IVIg or purified human
IgG. As shown, mean fluorescence levels measured on
CD19
+CD27
high cells before treatment remained unchanged 7
days after IVIg infusion (Figure 4 middle and right panels).
Clinical evolution in relation to day 7 plasmacytosis in
GBS.
Finally, we sought to determine if IVIg-related plasmacytosis
could serve as a marker of effectiveness of this treatment. Firstly,
we plotted plasma cell counts 7 days post-IVIg and time to
improvement of one GBS disability-grade, in order to assess the
possible correlation between the number of IVIg-mobilized
plasma cells and clinical improvement (Figure 5A). Retrospective
analysis was limited to severely disabled patients in order to avoid
bias related to potential deficiencies in minor symptom recording.
We found a strong negative correlation between the absolute
number of IVIg-mobilized plasma cells and time to improve one
GBS disability-grade in both retrospective and prospective studies
(r=20.52, p=0.0031, n=30, r=20.47, p=0.0028, n=40,
respectively; Figure 5A).
Secondly, GBS patients were divided into two groups depending
on whether they had or had not shown a significant plasmacytosis
($ 200 plasma cells/mL) on the 7
th day of treatment. Prominent
IVIg-Related Plasmacytosis
PLoS ONE | www.plosone.org 3 May 2008 | Volume 3 | Issue 5 | e2109Figure 1. IVIg-related peripheral plasmacytosis peaks on day 7 of treatment in retrospective study. (A) Mean absolute number of
plasma cells in IVIg-treated GBS (n=58, upper panel), CIDP (n=7, middle panel), and MG (n=38, lower panel) patients. Severely disabled GBS patients
(disability grade 3 or more) received IVIg only, whereas CIDP and MG patients received IVIg and steroids at admission (day0). (B) Mean plasma cell
counts in non-IVIg-treated patients over a 14-day period following admission. Severely disabled GBS patients (n=78, upper panel) were treated with
plasma exchange at admission (day0). Moderately disabled GBS patients (disability grade 2 or less, n=21, middle panel) and non-autoimmune
patients (n=104, lower panel) did not receive any immunotherapy during admission. At each time point, the number of patients with recorded white
blood cell count is indicated. Data are mean 6 s.e.m.
doi:10.1371/journal.pone.0002109.g001
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severely disabled patients in retrospective and prospective
analyses, respectively. Importantly, the two groups did not differ
in any clinical prognostic factors, including intervals between
motor deficit onset and treatment initiation (p=0.27, p=0.26,
respectively), age (p=0.93, p=0.98, respectively), preceding
diarrhoea (p.0.99, p=0.51, respectively), and rapid disease onset
(p=0.44, p=0.40, respectively). Patients having shown a plasma-
cytosis greater than or equal to 200 plasma cells/ml on the 7
th day
of treatment recovered faster than those who had not shown such
an expansion (p=0.011, p,0.0001, respectively; Figure 5B). More
patients having presented with a prominent IVIg-related plasma-
cytosis achieved independent walking at day 56, compared with
the others (p=0.0069, p=0.0095, respectively).
A more detailed analysis of the consecutive population revealed
that patients exhibiting more than 200 IVIg-mobilized plasma
cells/ml showed less severe GBS disability-grade at day 14 (3.1 6
0.94 vs 4.2 6 1.1, p=0.0031, data not shown). In addition, the
patient group with a prominent IVIg-related plasmacytosis less
frequently required mechanical ventilation (p=0.0073) and for
shorter time than the group not showing IVIg-related plasmacy-
tosis (18 6 4.0 days, n=3 vs 39 6 16 days, n=10, p=0.0034,
data not shown).
Discussion
Here we show that a prominent plasmacytosis was very
frequently associated with administration of IVIg in autoimmune
patients. More importantly, the level of circulating plasma cells on
the 7
th day of IVIg treatment correlated with clinical improvement
in patients with GBS. These findings indicate that plasma cell
count on the 7
th day of IVIg will be useful to distinguish patients
that have beneficial IVIg effects from those who would need more
individualized treatment, and to reconsider the treatment regimen
during the acute phase of GBS in the latter.
Low levels of circulating CD19
+CD27
high plasma cells were
occasionally detected in healthy individuals (5.2 6 2.4 cells/ml,
n=22, data not shown) or in untreated autoimmune patients in
our own study (Figure 2C). A fugacious plasmacytosis is in fact a
well known physiological consequence of any recent antigenic
stimulation [15,19,20], but typically much less than 100
lymphoplasmocytoid cells can be found in one microliter of blood
in such occasions, even in autoimmune patients with active disease
flares [14]. Here, we verified that a prominent plasmacytosis was
not a disease- or an infectious-related event. We also showed that
IVIg-mobilized plasma cells were not IVIg-specific (Figure 4
middle panel), and therefore did not simply reflect an immuniza-
tion against the infused products.
A very significant proportion of CD19
+CD27
high plasma cells
on the 7
th day of IVIg were detected in all GBS patients, as well as
in other autoimmune patients (Figure 2C). GBS patients presented
with significantly more day 7 plasma cells (31.2 6 16.1% among
CD19
+ B cells, n=40), compared with other autoimmune patients
(CIDP; 20.1 6 15.4%, n=14, p=0.0092, MG; 8.3 6 2.9%, n=7,
p,0.0001, IM; 5.3 6 2.7%, n=6, p,0.0001; Figure 2C left
panel). The less prominent plasma-cell mobilization in MG and
IM patients could be related to the fact that these patients received
steroids either before or during IVIg infusion. However, GBS and
CIDP groups were homogenous in terms of age, sex and treatment
received. Therefore, we can only postulate that IVIg-related
plasmacytosis would be more pronounced in the context of an
ongoing immune response, compared to chronic conditions such
as CIDP. In order to test that hypothesis, IVIg-related plasma-
cytosis should be measured in healthy controls.
Figure 2. Prospective analysis of plasmacytosis in autoimmune patients. (A) Cytometric analysis of circulating CD19
+CD27
high plasma cells
on day 0 and day 7 of IVIg treatment in a representative GBS patient. Proportions of CD19
+CD27
high plasma cells among CD19
+ cells are indicated. (B)
Peripheral CD19
+CD27
high plasma cell kinetics in representative GBS patients. (C) Proportions among CD19
+ cells (left panel) and absolute numbers
(right panel) of IVIg-mobilized CD19
+CD27
high plasma cells. GBS (disability grade 3 or more, n=40) and CIDP (n=14) patients received IVIg only,
whereas MG (n=7) and IM (n=6) patients received IVIg and steroids. Data are mean 6 s.e.m. Mean values were compared using Mann-Whitney U
test.
doi:10.1371/journal.pone.0002109.g002
IVIg-Related Plasmacytosis
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+CD27
high cells are immature. (A) Representative analyses of circulating and bone marrow
CD19
+CD27
high cells in a GBS patient 7 days after IVIg infusion and in a healthy bone marrow donor. (B) Control mature medullary CD19
+CD27
high
plasma cells (as identified in panel A, right) were CXCR4
highCD138
highHLA-DR
low (gray line). Circulating IVIg-mobilized CD19
+CD27
high plasma cells
were CXCR4
lowCD138
lowHLA-DR
high (solid line). Isotype controls were presented (dotted line). (C) Balance between immature (HLA-DR
high) and
mature (HLA-DR
low) plasma cells (PCs) in IVIg-treated patients 7 days after treatment. GBS (disability grade 3 or more, n=40) and CIDP (n=14)
patients received IVIg only, whereas MG (n=7) and IM (n=6) patients received IVIg and steroids. Data are mean 6 s.e.m. Comparisons of indicated
mean values were performed by use of Mann-Whitney U test.
doi:10.1371/journal.pone.0002109.g003
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PLoS ONE | www.plosone.org 6 May 2008 | Volume 3 | Issue 5 | e2109In GBS patients, the magnitude of IVIg-related plasmacytosis
correlated with improvement of neurological function, including
achievement of independent locomotion and discontinuation of
mechanical ventilation. Importantly, clinical prognostic factors
were demonstrated to be homogenous between patients with a
prominent IVIg-related plasmacytosis and the others, indicating
that IVIg-mobilized plasma cells could be served as a biological
prognostic marker. Recently, a prognostic scoring system for GBS
has been reported to predict the capacity of independent
locomotion at 6 months [5]. This scoring system is based on
age, previous episode of diarrhoea and GBS disability-grade at 2
weeks of treatment. We evaluated how day 7 plasmacytosis
performs, compared with this score (Erasmus GBS outcome score).
In the consecutive population we studied, we show that the group
of patients with a prominent IVIg-related plasmacytosis will
recover faster than the others according to classic criteria
Figure 4. IVIg-mobilized plasma cells are neither IVIg- nor human IgG-specific. CD19
+CD27
high plasma cells were analyzed following
intracellular staining with anti-IgG FITC, IVIg FITC and human IgG FITC before (dotted line) and 7 days after IVIg infusion (black line). One
representative individual out of 17 analyzed.
doi:10.1371/journal.pone.0002109.g004
Figure 5. Correlation between the number of plasma cells and clinical improvement in retrospective (n=30, left panels) and
prospective (n=40, right panels) studies. (A) Strong negative correlation in both studies between the absolute number of IVIg-mobilized
plasma cells (PCs) and time to improve one GBS disability-grade. Correlation was analyzed using Spearman test. (B) Day 7 plasmacytosis correlates
with faster clinical improvement. Kaplan-Meier analysis of time to one disability-grade improvement following IVIg in relation to day 7 plasma cell
counts enumerated on a routine hematology analyzer and confirmed by blood smear exam.
doi:10.1371/journal.pone.0002109.g005
IVIg-Related Plasmacytosis
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months). We show that the Erasmus GBS outcome score in that
group could also have predicted a more favourable evolution,
compared with the other (p=0.0018). As stated above, retrospec-
tive analysis was limited to severely disabled patients in order to
avoid bias related to minor symptom recording. In that
retrospective population-based study, we also show that the group
of patients with a prominent IVIg-related plasmacytosis will
recover faster than the other. Interestingly, we found that the
Erasmus GBS outcome score would not have predicted a more
favourable evolution in that group (p=0.55). Therefore, plasma-
cell monitoring appears to have an added value over the Erasmus
GBS outcome score for the prognostic evaluation of severe GBS
patients.
Further observations in the 5 GBS patients who relapsed within
28 days after IVIg give further comfort to the prognostic value of
day 7 plasmacytosis. These patients had significantly less
circulating day 7 plasma cells, compared with the others (68 6
72 cells/ml, n=5 vs 369 6 426 cells/ml, n=35, p=0.0079), and
were treated with several courses of IVIg. Despite repeating IVIg
treatment, 2 such refractory patients died 28 days and 100 days
after the first IVIg course. It is therefore unlikely that repeating
IVIg treatment in refractory patients will be adequate. Cost would
be reduced, and treatment could be optimized by defining which
patients would benefit from an alternative treatment instead of
receiving several IVIg courses. However, more patients need to be
studied before we can recommend not repeating IVIg infusion in
the absence of plasmacytosis after the first IVIg course.
The mobilization of a large number of plasma cells concurrently
with clinical improvement might seem surprising. The detection of
these cells is rather typically associated with autoimmune disease
flares, for instance in multiple sclerosis and systemic lupus
erythematosus [14,21]. Our data, as counter-intuitive as they
may seem, are nevertheless in good agreement with proposed
models of plasma-cell dynamics during humoral immune respons-
es [15]. According to the later, newly generated plasmablasts enter
into competition with older cells for their medullary niches.
Similarly, we would like to propose that following IVIg treatment,
a large ‘‘wave’’ of mobilized cells induces a significant renewal of
the repertoire of antibody-secreting cells. A ‘‘re-equilibration’’ of
the repertoire of circulating antibodies in favour of non-pathogenic
antibodies could then ensue. As stated above, it is strongly
suspected that antibody-secreting plasma cells which cross-react
with nervous structures are induced during a preceding infectious
episodes [22], and reside in the survival niches of the bone marrow
in patients with GBS [23]. One can imagine that a proportion of
these cells, among others, would be chased from the marrow by a
wave of new polyclonal immigrants [15,24]. Given the long half-
life of antibodies, this mechanism may be difficult to reconcile with
the rapid mode of action of IVIg. Other mechanisms have been
proposed to account for the anti-inflammatory effect of IVIg
[25,26]. It is now generally accepted that IVIg has multiple
therapeutic effects that would act in concert [27]. IVIg could, for
instance, directly influence plasma-cell survival [28,29]. Plasma-
cell mobilization could nevertheless have a long lasting impact on
the pool of long-lived plasma cells that are not affected by classic
immunomodulation treatments [30]. This particular mode of
action of IVIg could explain its superiority over steroids in certain
indications such as GBS [12,31,32]. Interestingly, it is notable that
Pemphigus Vulgaris patients who do not respond to steroids plus
immunosuppressive agents can nevertheless respond to IVIg [33].
IVIg promotes immature plasma-cell mobilization in patients
with GBS, CIDP, MG and IM (Figure 3C). Even if it has been
demonstrated that IVIg could accelerate the in vitro maturation of
B lymphocytes [34], the origin of the mobilized plasma cells [35]
and the mechanism through which this treatment induces their
mobilization remain unclear. It will therefore be interesting to
determine how IVIg is able to influence the maturation, the
migration, and ultimately the replenishment of plasma cells.
In spite of IVIg treatment, approximately 20% of the patients
with GBS are unable to walk without assistance after 1 year [6,7].
Day 7 plasma-cell monitoring will be helpful to predict which
patients will improve after IVIg treatment, and therefore will
prompt the early implementation of more individualized thera-
peutic strategies in such patients at a greater risk of poor outcome.
Supporting Information
Figure S1 IVIg-mobilized CD19
+CD27
high plasma cells were
IgG-secreting cells. (A) A representative 4-colour cytofluorometric
analysis of GBS PBMCs 7 days after initiation of IVIg infusion.
Intracellular analysis revealed that post-IVIg CD19
+CD27
high
plasma cells (gated as indicated) were intracellular IgG
+IgM
2 and
membrane CD38
+CD138
+ (insets). (B) Correlation between flow
cytometry-enumerated CD19
+CD27
high cells and ELISPOT-
enumerated IgG-secreting cells (SCs) in 6 GBS patients treated
with IVIg. Cytofluorometric analysis and ELISPOT assay were
simultaneously performed 7 days post-IVIg infusion. Correlation
was analyzed using Spearman test.
Found at: doi:10.1371/journal.pone.0002109.s001 (10.10 MB
TIF)
Methods S1
Found at: doi:10.1371/journal.pone.0002109.s002 (0.03 MB
DOC)
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